Secondary minimally differentiated acute leukemia with plasmacytoid dendritic cell differentiation (pDC-AML) following chemoradiotherapy for Ewing sarcoma in a child: biallelic EZH2 inactivation.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
The diagnosis of myeloid neoplasms with plasmacytoid dendritic cell (pDC) differentiation is challenging due to immunophenotypic overlap with BPDCN. We describe an 8-year-old boy with a history of Ewing sarcoma treated with chemotherapy and radiotherapy who developed acute myeloid leukemia (AML) two years later. Bone marrow met criteria for AML with minimal differentiation: blasts expressed CD34, CD117, CD33, and CD7 but lacked myeloperoxidase; scattered TCF4+ cells indicated a minor pDC component. Concurrently, 23.6% of pleural fluid cells exhibited a classic pDC immunophenotype (CD123+bright, CD304+, CD4+, HLA-DR+bright, CD56-, TCF4+ by immunohistochemistry). Genetic analysis revealed a complex karyotype with del(7q), biallelic EZH2 inactivation, 3q duplication involving MECOM, and PTPN11 mutation. This pediatric therapy-related case with a distinct genetic profile expands the spectrum of pDC-AML and highlights the diagnostic pitfall of CD123+/CD4+ immunophenotype in myeloid neoplasms with pDC differentiation.